Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Curr Probl Cardiol ; 48(11): 101918, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37399857

RESUMEN

Hypertension is a global epidemic, affecting around 30.4% of the population and being the leading preventable risk factor for death. Despite the availability of numerous antihypertensive agents, less than 20% of individuals have their blood pressure controlled. Resistant hypertension poses a challenge, but a new class of medication, aldosterone synthase inhibitors (ASI), shows promise. ASI reduces aldosterone production by inhibiting aldosterone synthase. This review article focuses on Baxdrostat, a highly potent ASI currently in phase 3 trials. It discusses the drug's biochemical pathway, efficacy trials in animals and humans, and its potential in uncontrolled hypertension, chronic kidney disease, and primary aldosteronism.


Asunto(s)
Aldosterona , Hipertensión , Animales , Humanos , Aldosterona/uso terapéutico , Citocromo P-450 CYP11B2 , Hipertensión/tratamiento farmacológico , Antihipertensivos/farmacología , Antihipertensivos/uso terapéutico , Antagonistas de Receptores de Mineralocorticoides/farmacología , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA